The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on February 16, 2026 for Renosen Pharmaceuticals Pvt Ltd

Pledge ReleasedOwnership Changes View source PDF Explain this filing

SENORES · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.1%Reaction day

₹791.15

prior close

₹795.60

announcement price

In-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+1.0%-0.9% vs market

Pharmaceuticals peers, median of 157sector+0.2%-0.2% vs sector

On the reaction day the stock moved 0.9 pts less than Nifty Microcap 250 and 0.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.8

10m

+0.5

15m

+0.2

30m

-0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.1+1.0-0.9+0.2-0.2

Next day

+3.9+1.3+2.6+0.6+3.2

+2.5-0.2+2.7-0.4+2.9

+2.5-0.3+2.8-0.6+3.1

+0.3-0.2+0.5-0.3+0.6

-1.0-1.4+0.4-1.6+0.6

-1.3-1.0-0.3-0.6-0.7

15d

-6.5-6.3-0.2-4.2-2.3

-5.4-9.0+3.6-5.8+0.4

+12.9+3.5+9.4+1.4+11.4

+43.2+4.6+38.6+4.1+39.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Renosen Pharmaceuticals Private Limited (formerly Senores Lifesciences Pvt Ltd), a promoter entity of Senores Pharmaceuticals, has released a pledge on 4,00,000 equity shares (about 0.87% of total share capital). The pledge was originally created in favor of Bajaj Finance Limited. The release was executed on February 13, 2026, and the disclosure was filed with BSE and NSE on February 16, 2026. After this release, Renosen Pharmaceuticals holds 27,08,719 shares (5.88% of capital) with zero pledged shares remaining. The pledge was linked to a loan, and its release suggests the obligation has been fulfilled.

Likely market impact

Positive for shareholders — the release removes the overhang of potential forced selling and indicates the promoter entity has likely repaid the loan to Bajaj Finance, improving its balance sheet position.